All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Azercabtagene zapreleucel granted FDA fast track designation for the treatment of patients with R/R DLBCL
On March 19, 2025, the U.S. Food and Drug Administration (FDA) granted fast track designation to azercabtagene zapreleucel (azer-cel), an off-the-shelf, CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.1 This announcement is supported by findings from a phase Ib trial.
Phase Ib trial
Clinical data from an ongoing phase Ib trial have shown considerable promise, especially in patients who have not responded to multiple previous therapies, including autologous CAR T. Azer-cel incorporates lymphodepletion chemotherapy and interleukin-2 (IL-2) to improve CAR T persistence and efficacy. The safety profile was manageable, with no instances of immune effector cell-associated neurotoxicity syndrome (ICANS).1
Azer-cel is designed to address the logistical issues associated with autologous CAR T therapies, such as extended manufacturing times and restricted patient access. By utilizing pre-manufactured donor T-cells, azer-cel enables swift treatment delivery.1
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
